Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Collongues Nicolas, Durand-Dubief Françoise, Lebrun-Frenay Christine, Audoin Bertrand, Ayrignac Xavier, Bensa Caroline, Bigaut Kévin, Bourre Bertrand, Carra-Dallière Clarisse, Ciron Jonathan, Defer Gilles, Kwiatkowski Arnaud, Leray Emmanuelle, Maillart Elisabeth, Marignier Romain, Mathey Guillaume, Morel Nathalie, Thouvenot Eric, Zéphir Hélène, Boucher Julie, Boutière Clémence, Branger Pierre, Da Silva Angélique, Demortière Sarah, Guillaume Maxime, Hebant Benjamin, Januel Edouard, Kerbrat Anne, Manchon Eric, Moisset Xavier, Montcuquet Alexis, Pierret Chloé, Pique Julie, Poupart Julien, Prunis Chloé, Roux Thomas, Schmitt Perrine, Androdias Géraldine, Cohen Mikael
Аннотация
OBJECTIVE: To develop evidence-based recommendations to manage the coexistence of cancer and multiple sclerosis (MS).
METHODS: The French Group for Recommendations in MS collected articles from PubMed and university databases covering the period January 1975 through June 2022. The RAND/UCLA method was employed to achieve formal consensus. MS experts comprehensively reviewed the full-text articles and developed the initial recommendations. A group of multidisciplinary health care specialists then validated the final proposal.
RESULTS: Five key questions were addressed, encompassing various topics such as cancer screening before or after initiating a disease-modifying therapy (DMT), appropriate management of MS in the context of cancer, recommended follow-up for cancer in patients receiving a DMT, and the potential reintroduction of a DMT after initial cancer treatment. A strong consensus was reached for all 31 recommendations.
CONCLUSION: These recommendations propose a strategic approach to managing cancer risk in PwMS.